Anti-NMDAr Encephalitis and COVID-19 in a Patient With Systemic pANCA-Vasculitis and Recurrent Varicella Zoster Infection

João Moura, MD1, Sara Duarte, MD1, Ana Sardoeira, MD1, João Neves-Maia, MD2, Joana Damásio, MD1,3, Ricardo Taipa, MD, PhD1,3,4, Paula Carneiro, MD5, Esmeralda Neves, MD5, Ana Campar, MD2,3,6, and Ernestina Santos, PhD1,3,6

Abstract

Introduction: There is a complex interplay between systemic autoimmunity, immunosuppression, and infections. Any or all of these can result in neurologic manifestations, requiring diligence on the part of neurologists. Case report: We herein report a case of a patient on immunosuppressive treatment for a vasculitis that resulted in zoster meningoencephalitis. This was further complicated by the development of anti-NMDAr encephalitis, the etiology of which is undetermined and further discussed in this paper. The patient eventually developed COVID-19 during hospitalization, succumbing to the respiratory infection. Conclusion: This case emphasizes that post-infectious autoimmune disorders are becoming increasingly recognized and that they should still be considered in patients who are on immunosuppression. Practitioners should be aware of the complex relationship between autoimmunity and immunosuppression and consider both throughout the disease course.

Keywords

vasculitis, varicella zoster, anti-NMDAr, encephalitis, COVID-19

Case Description

A 76-year-old man, with past medical history of right parietal stroke in 2014, in the distal branches of the medial cerebral artery (MCA), and acute ischemic cardiopathy in June of 2016, was admitted in July of 2016 with a prolonged history of anorexia, fatigue, fever, nonproductive cough, and epistaxis accompanied by acute kidney injury, microcytic anemia (Hb 8.6 g/dL), eosinophilia (900–1500/μL), elevated erythrocyte sedimentation rate (ESR) (94 mm/h), and elevated IgG (3184 mg/dL) with positive pANCA (MPO) antibodies. A diagnosis of ANCA-associated vasculitis was assumed after exclusion of other causes and treatment with prednisolone 40 mg/day and cyclophosphamide 750 mg 3/3 weeks initiated and tapered in the outpatient clinic.

In September 2016, he developed a painful vesicular eruption in the right gluteal region with extension to the perineum, followed by perianal pain and urinary/fecal incontinence. Neurological examination revealed weakness in dorsi flexion of the left foot, left S2–S5 hypoesthesia and hypotonic anal sphincter. Lumbo-sacral MRI showed no compressive lesions, and a lumbar puncture was performed, revealing lymphocytic pleocytosis and a positive VZV PCR (Table 1 A). The patient was diagnosed with cauda equina syndrome secondary to zoster virus (VZV) meningoencephalitis and admitted for intravenous acyclovir treatment. After discharge, cyclophosphamide was suspended and maintenance treatment with azathioprine 150 mg/day and prednisolone 20 mg/day was implemented. The complaints of perianal pain persisted. The neurological examination revealed bilateral lower limb hypoesthesia in a length-dependent distribution, right S2–S5 hypoesthesia and absent bulbocavernous reflex. Electromyography (EMG) findings were consistent with a

1Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2Department of Internal Medicine, Centro Hospitalar Unniversitário do Porto, Porto, Portugal
3Unit for Multidisciplinary Research in Biomedicine (UMIB), Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
4Neuropathology Unit, Department of Neurosciences, Centro Hospitalar Universitário do Porto, Porto, Portugal
5Immunology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal
6Clinical Immunology Unit, Centro Hospitalar Universitário do Porto, Porto, Portugal

Corresponding Author:
João Moura, Department of Neurology, Centro Hospitalar Universitário do Porto, Largo Professor Abel Salazar, Porto 4099-001, Portugal.
Email: moura.neuro@chporto.min-saude.pt

Institutional
sensorimotor axonal polyneuropathy, which was stable on repeat EMG in 2019 and nerve biopsy showed moderate axonal loss, particularly of small, myelinated fibers, with occasional clusters of regenerating fibers also present (Figure 1). No amyloid deposition or inflammatory infiltrates were visualized. The neurological findings were maintained in the following visits, without considerable improvement of the pain despite adjusted therapy.

In June of 2018, he was admitted in the emergency department with a 5-day history of left eye pain, redness, and blurred vision. He was diagnosed with ophthalmic herpes zoster based on clinical examination by the ophthalmologist who described edema and stromal infiltrates in the inferior half of the left eye. He was started on valaciclovir. Continued follow up by ophthalmology led to the diagnosis of refractory herpes ophthalmicus in April of 2019, and azathioprine suspended given the risk of permanent vision loss.

At this point, the ESR was 40 mm/h, lymphocyte count 900/μL and the glomerular filtration rate stabilized at 30 mL/min, with inactive urinary sediment. Prednisolone 5 mg was maintained and standing acyclovir was started.

In November of 2020, the patient was admitted to the emergency department with an isolated receptive aphasia and the CT scan revealed a left tempo-parietal stroke (NIHSS = 7). Recombinant tissue plasminogen activator (rTPA) was administered around 3 hours after symptoms onset. CT angiography did not reveal any evidence of thrombosis, extracranial or intracranial stenosis. Reevaluation after 24 hours showed persistence of the aphasia, and hemorrhagic transformation was confirmed via CT Scan, showing a cortico-subcortical hematoma rupturing to the ventricular system. He was admitted to the Stroke Unit, developing periods of agitation for which haloperidol 2 mg was administered. A negative SARS-CoV-2 test was provided before admission. He developed a fever and progressive deterioration of the level of consciousness in the following days, associated with rise of blood inflammatory markers (ESR at 85 mm/h and C reactive protein at 160 mg/L). Acute kidney injury was diagnosed (CrS 1.76 mg/dL) and acyclovir suspended given its nephrotoxic potential. Urinalysis revealed leukocyturia and nitrituria, for which piperacillin-tazobactam was initiated. On the eighth day of hospitalization, as the patient displayed neck stiffness and altered mental status and fever persisted, a lumbar puncture was performed for a possible meningoencephalitis. Based on cerebrospinal fluid marked lymphocytic pleocytosis (Table 1. B), the possibilities of a vasculitis flare vs zoster relapse (given the antiviral interruption) were considered. Treatment with acyclovir 10 mg/kg/day was started until further laboratory analysis was available. A brain MRI revealed no additional findings (Figure 2). Serum pANCA antibodies were negative. Viral PCR of CSF was negative for HSV1, HSV 2, and VZV. Strikingly, immunofluorescent staining of serum and CSF revealed marked positivity for anti-NMDAR autoantibodies in two separate occasions (Table 1. C). Treatment with IV methylprednisolone 1g for 5 days and IVIg 2 g/kg for 4 days was added. A CSF evaluation at the 18th day revealed improvement of the pleocytosis (Table 1. D), but without clinical response. Antiviral treatment was continued. A full-body CT and a testicular US were unremarkable, except for signs of chronic pulmonary embolism on the CT, for anticoagulation was initiated. Weaning of prednisolone was started and mensal cycles of intravenous Immunoglobulin (IVIg) programed. The patient remained unresponsive, with the eyes open, and symmetrically mobilizing the four limbs throughout the entire hospitalization.

At the 42th day of his long stay, he developed a fever and nonproductive cough, and a SARS-CoV-2 PCR was ordered, which came positive. He was transferred to a COVID-19 dedicated infirmary where he died 16 days later from respiratory failure associated with viral pneumonia.

### Discussion and Conclusions

This is an educational case of a patient with a rare systemic inflammatory condition, who developed both infectious and secondary autoimmune complications during his course of treatment.

---

**Table 1. CSF analysis during different time-points of the clinical history.**

| Parameters          | A              | B 2020 (day 0) | C 2020 (day 5) | D 2020 (day 18) |
|---------------------|----------------|---------------|----------------|-----------------|
| Leucocytes (cell/mm³) | 10 (10 MMN, 100.0%) | 290(198 MMN, 68.3%) | 260(177 MMN, 68.1%) | 14 (11 MMN, 78.6%) |
| Glucose⁹          | 0.45 g/L       | 0.83 g/L      | 0.76 g/L       | 0.58 g/L        |
| [Serum Glucose]    | [1.1 g/L]      | [1.3 g/L]     | [1.2 g/L]      | [0.9 g/L]       |
| Protein           | 0.54 g/L       | 0.70 g/L      | 0.60 g/L       | 0.41 g/L        |
| PCR               | VZV: +         | VZV: -        | Not tested     | Not tested      |
| HSV 1/2           | HSV 1/2: -     |                | anti-NMDAr +   | Not tested      |
| Immunology        | Not tested     |                | anti-NMDAr +   |                |

The specific time-points to which the results correspond are specified throughout the main text.

Abbreviations: MMN, mononuclear cell; PCR, polymerase chain reaction; VZV, Varicella Zoster Virus; HSV, Herpes Simplex Virus; NMDAr, N-methyl-D-aspartate receptor.
The presence of eosinophilia and pANCA (MPO) antibodies gave rise to the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), previous Churg-Strauss syndrome, with cardiac, renal, lung, and suspected central and peripheral neurological involvements. Namely, in the absence of other cause, the previous ischemic stroke reflects a possible early involvement of the central nervous system. In fact, isolated cerebral infarction as the presenting symptom of ANCA-associated vasculitis has been reported. The peripheral nervous system was also latter involved by a sensory-motor axonal neuropathy for which no other cause was identified.

Following the induction (prednisolone and cyclophosphamide) and maintenance (prednisolone and azathioprine) treatment for vasculitis, the patient developed VZV meningoradiculitis (with congruous herpetic rash) and herpes zoster ophthalmicus, respectively. These events were considered secondary to the immunosuppressive medication, in an elderly patient with chronic renal failure, both well-known factors associated with endogenous immune decline. In fact,

![Figure 1. Histology of sural nerve biopsy: Moderate axonal neuropathy, particularly affecting small, myelinated fibers and with a symmetric involvement of the different fascicles. There were rare degenerating fibers (arrow) and occasional small regenerating clusters. No inflammation. Toluidine blue, scale bar: 500 μm (A) and 50 μm (B).](image-url)
both cyclophosphamide and azathioprine have been shown to directly correlate to the recrudescence of VZV and development of post-herpetic neuralgia. However, one must consider other factors as potentially predisposing for the recrudescence of the infection, not only related to the immune-senescence or systemic vasculitis, but also to an underlying malignancy, since both conditions are associated with immunosuppression.

This case highlights the intricate management of immunosuppression, since when the patient was kept only on prednisolone because of the multiple zoster recurrences he developed a probable flare of vasculitis. This in turn may have caused a second ischemic stroke with subsequent hemorrhagic transformation, for which vasculitis may have further contributed. The etiology of this ischemic event was thoroughly explored, with exclusion of the most common causes of vascular disease by means of electrocardiography, electrocardiogram and angiography.

Clinical deterioration during hospitalization, associated with fever and meningeal signs, led to the investigation of a possible meningoencephalitis, unraveling marked positivity for anti-NMDAr in the CSF, with no evidence of VZV.

Based on the presence of altered mental status, CSF pleocytosis and seropositive for anti-NMDAr, an autoimmune encephalitis was considered. The brain MRI was normal, with no signs of increased signal on T2-weighted FLAIR imaging in the medial temporal lobes. As suggested by Graus et al, the diagnosis of autoimmune encephalitis can be made if antineural antibodies are detectable, even in the absence of imaging findings. In this case, no better explanation for the clinical picture was present, with exclusion of infectious and other inflammatory conditions.

NMAD encephalitis is known to occur as a paraneoplastic disorder, post-infectious process or may be idiopathic. In our patient, a thorough investigation for malignancy was performed including full-body CT and testicular ultrasound, which were unremarkable. While the presence of pulmonary emboli could point toward malignancy-related hypercoagulability, this may have simply occurred in the setting of prolonged hospitalization.

Herpesviruses are a recognized trigger for anti-NMDAR antibodies. Given their homology, we may speculate that the same mechanism of molecular mimicry proposed for HSV-1 may occur for VZV. It has been suggested that other agents such as mycoplasma pneumoniae might also trigger anti-NMDAR antibodies, especially in younger patients. With regard to the VZV associated anti-NMDAR encephalitis hypothesis, despite being rare, there have been several reported cases in the literature. Of these cases, two patients had underlying malignancy including a teratoma and non-teratomatous gynecologic malignancy, while one did not have any identified malignancy. This post-viral autoimmune encephalitis might progress into chronicity, with some reported cases of herpetic encephalitis associated with step-wise hippocampal sclerosis.

In this case, at the time of the diagnosis of the anti-NMDAR encephalitis, CSF PCR was negative for VZV. Unfortunately, VZV IgG was not tested in the CSF, which would have been useful in supporting the association.

We might argue that the last known manifestation of VZV activity occurred one year before, by means of herpes zoster ophthalmicus, which seems too long to consider the association. However, primarily with HSV, there have been reports of delayed diagnosis and persistent antibody presence farther out. Furthermore, VZV encephalitis might have been unnoticed at presentation.

Overall, taking into account the patients age and the diseases time course, post-herpetic anti-NMDAr seems a more plausible explanation. In the future, it would be interesting to study the immunogenic potential of clinically silent VZV infection and resulting autoimmune encephalitis. Immunosuppression is the mainstay of treatment, differing from the treatment of infectious causes, which highlights the importance of considering this etiology in clinical practice.

At the end, this patient with multiple processes of autoimmune, infectious and possibly neoplastic etiology, succumbed to hospital-acquired COVID-19, in the midst of the pandemic.

Our case highlights several points. Immunosuppression puts patients at risk for infections like VSV. Infections in turn can put patients at risk for autoimmune disorders, particularly in the increasingly recognized association between herpesviruses and anti-NMDAR encephalitis. Thus,

Figure 2. FLAIR MRI showing old ischemic lesions on the right temporal, parietal, and occipital topography. On the left occipitoparietal region, there are signs of a recent ischemic event with hemorrhagic transformation in the left middle cerebral artery territory, corresponding to the more recent stroke. This location is consistent with the clinical signs of expressive aphasia.
it is important to always consider a wide differential diagnosis in complex patients with underlying or iatrogenic perturbations of the immune system.

Author contributions
JM collected the data and conceived the article. RT did the neuropathology study. SD, AS, JD, RT, PC, EN, AC and ES reviewed and critiqued the paper.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics
This case report did not include any data that may identify the patient or its relatives. No approval from the ethics committee was needed.

Availability of Data and Materials
The information was obtained through the electronic clinical records. No reference was made to any feature that may identify the patient or its relatives.

ORCID iDs
João Moura https://orcid.org/0000-0002-4212-906X
Paula Carneiro https://orcid.org/0000-0001-8760-4015

References
1. Robson JC, Grayson PC, Suppiah R, et al. American college of rheumatology and european league against rheumatism 2017 provisional classification criteria for granulomatosis with polyangiitis. Rheumatol(United Kingdom) 2017.
2. Ito Y, Suzuki K, Yamazaki T, Yoshizawa T, Ohkoshi N, Matsumura A. ANCA-associated vasculitis (AAV) causing bilateral cerebral infarction and subsequent intracerebral hemorrhage without renal and respiratory dysfunction. J Neurol Sci. 2006;240:99-101. doi:10.1016/j.jns.2005.07.003.
3. Garnier C, Ribes D, Chauveau D, et al. Zoster after cyclophosphamide for systemic lupus erythematosus or vasculitis: Incidence, risk factors, and effect of antiviral prophylaxis. J Rheumatol. 2018;45:1541-1548. doi:10.3899/jrheum.180310.
4. Cottone M, Renna S. Incidence of HSV and HPV with azathioprine. Nat Rev Gastroenterol Hepatol. 2009;6:444-445. doi:10.1038/nrgastro.2009.110.
5. Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open Med. 2013.
6. Kronbichler A, Leierer J, Gauckler P, Shin JI. Comorbidities in ANCA-Associated Vasculitis. Rheumatol(United Kingdom). 2020;59:iii79-iii83. doi:10.1093/rheumatology/kez617.
7. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391-404.
8. Dale RC, Nosadini M. Infection-triggered autoimmunity: The case of herpes simplex virus type 1 and anti-NMDAR antibodies. Neurology(R) neuroimmunology & neuroinflammation. 2018;5:e471.
9. Salovin A, Glanzman J, Roslin K, Armande K, Lynch DR, Panzer JA. Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection. Neurology - Neuroimmunology Neuroinflammation. 2018;5:e458. doi:10.1212/NXI.0000000000000458.
10. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11-18.
11. Solís N, Salazar L, Hasbun R. Anti-NMDA Receptor antibody encephalitis with concomitant detection of Varicella zoster virus. J Clin Virol. 2016;83:26-28. doi:10.1016/j.jcv.2016.08.292.
12. Schäbitz W-R, Rogalewski A, Hagemeister C, Bien CG. VZV brainstem encephalitis triggers NMDA receptor immuno-reaction. Neurology. 2014;83:2309-2311. doi:10.1212/WNL.00000000000001072.
13. Popkirov S, Ismail FS, Grönnheit W, Kapauer M, Wellmer J, Bien CG. Progressive hippocampal sclerosis after viral encephalitis: Potential role of NMDA receptor antibodies. Seizure. 2017;51:6-8.
14. Dorcet G, Benateau M, Bost C, et al. Two Cases of Late-Onset Anti-NMDAR Auto-Immune Encephalitis After Herpes Simplex Virus I Encephalitis. Front Neurol. 2020;11:38.
15. Bradshaw MJ, Venkatesan A. Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management. Neurotherapeutics. 2016;13:493-508.
16. Aksamit AJ. Treatment of Viral Encephalitis. Neurol Clin. 2021;39:197-207.